ISPMD consensus on the management of premenstrual disorders

Archives of Women's Mental Health

Volumn 16, Issue 4, 2013, Pages 279-291

  Nevatte, Tracy ^a   O'Brien, Patrick Michael Shaughn ^b   Bäckström, Torbjorn ^c   Brown, Candace ^d   Dennerstein, Lorraine ^e   Endicott, Jean ^f   Epperson, C Neill ^g   Eriksson, Elias ^h   Freeman, Ellen W ⁱ   Halbreich, Uriel ^j   Ismail, Khalid ^k   Panay, Nicholas ^l   Pearlstein, Teri ^m   Rapkin, Andrea ⁿ   Reid, Robert ^o   Rubinow, David ^p   Schmidt, Peter ^q   Steiner, Meir ^r   Studd, John ^l   Sundström Poromaa, Inger ^s   Yonkers, Kimberly ^t   more..

^a KEELE UNIVERSITY   (United Kingdom)

^b UNIVERSITY HOSPITAL OF NORTH STAFFORDSHIRE   (United Kingdom)

^c UMEÅ UNIVERSITY HOSPITAL   (Sweden)

^d UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^e UNIVERSITY OF MELBOURNE   (Australia)

^f Columbia University ^*  (United States)

^g UNIVERSITY OF PENNSYLVANIA   (United States)

^h UNIVERSITY OF GOTHENBURG   (Sweden)

ⁱ UNIVERSITY OF PENNSYLVANIA   (United States)

^j UNIVERSITY AT BUFFALO   (United States)

^k UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^l CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^m BROWN UNIVERSITY   (United States)

ⁿ UNIVERSITY OF CALIFORNIA   (United States)

^o QUEEN S UNIVERSITY   (Canada)

^p UNIVERSITY OF NORTH CAROLINA   (United States)

^q NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^r MCMASTER UNIVERSITY   (Canada)

^s Department of Woman and Child Health   (Sweden)

^t Department of Psychiatry ^*  (United States)

more..

Author keywords

Core premenstrual disorder; PMDD; PMS; Premenstrual dysphoric disorder; Premenstrual exacerbation; Premenstrual syndrome; Variant premenstrual disorder

Indexed keywords

ALPRAZOLAM; AMFEBUTAMONE; BENZODIAZEPINE DERIVATIVE; BUSPIRONE; CLOMIPRAMINE; DANAZOL; DESIPRAMINE; DESOGESTREL; DROSPIRENONE; ESTRADIOL; ESTROGEN; ETHINYLESTRADIOL; FLUOXETINE; GONADORELIN AGONIST; LEVONORGESTREL; MAPROTILINE; NORETHISTERONE; ORAL CONTRACEPTIVE AGENT; PLACEBO; PROGESTERONE; PSYCHOTROPIC AGENT; SEROTONIN UPTAKE INHIBITOR; SPIRONOLACTONE;

ANXIETY DISORDER; ARTICLE; BLOATING; BONE DEMINERALIZATION; CALCIUM INTAKE; CARBOHYDRATE INTAKE; CARDIOVASCULAR RISK; COGNITIVE THERAPY; CONSENSUS DEVELOPMENT; DELAYED ORGASM; DEPRESSION; DIARRHEA; DIET SUPPLEMENTATION; DISEASE CLASSIFICATION; DIZZINESS; DOSE RESPONSE; DRUG COST; DRUG DEPENDENCE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; EMOTIONAL DISORDER; ENDOMETRIUM ABLATION; ENDOMETRIUM HYPERPLASIA; ESTROGEN DEFICIENCY; FATIGUE; GYNECOLOGIST; HEALTH PERSONNEL ATTITUDE; HORMONE SUBSTITUTION; HOT FLUSH; HUMAN; HYSTERECTOMY; INSOMNIA; LIBIDO DISORDER; LOW DRUG DOSE; MASTALGIA; MEDICAL EXPERT; MEDICAL PRACTICE; MENSTRUAL CYCLE; MENSTRUAL IRREGULARITY; MENSTRUATION DISORDER; MOLECULAR PATHOLOGY; MOOD DISORDER; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROMODULATION; NEUROTRANSMISSION; ORGASM DISORDER; OSTEOPOROSIS; OVARIECTOMY; OVULATION INHIBITION; PALLIATIVE THERAPY; PATHOGENESIS; PREMENSTRUAL DISORDER; PREMENSTRUAL DYSPHORIC DISORDER; PREMENSTRUAL SYNDROME; PREVALENCE; PRIORITY JOURNAL; PSYCHIATRIST; PSYCHOLOGIST; PSYCHOSOMATIC DISORDER; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SALPINGOOOPHORECTOMY; SEXUAL DYSFUNCTION; VAGINA ATROPHY; VIRILIZATION; VITAMIN SUPPLEMENTATION; VITEX AGNUS CASTUS;

CONSENSUS; FEMALE; GROUP PROCESSES; HUMANS; PREMENSTRUAL SYNDROME; UNITED STATES;

EID: 84881128791     PISSN: 14341816     EISSN: 14351102     Source Type: Journal    
DOI: 10.1007/s00737-013-0346-y     Document Type: Article

References (106)

1. American Psychiatric Association (2000) Diagnostic and statistical manual of mental disorders. 4th ed, text revision. Washington: The Association
2. Andersch B, Wendestam C, Hahn L, Ohman R (1986) Premenstrual complaints. Prevalence of premenstrual symptoms in a Swedish urban population. J Psychosom Obstet Gynaecol 5:39-49
3. Andréen L, Nyberg S, Turkmen S, van Wingen G, Fernández G, Bäckström T (2009) Sex steroid induced negative mood may be explained by the paradoxical effect mediated by GABAA modulators. Psychoneuroendocrinology 34:1121-32
4. Angst J, Sellaro R, Merikangas KR, Endicott J (2001) The epidemiology of perimenstrual psychological symptoms. Acta Psychiatr Scand 104:110-16
5. Bäckström T, Boyl H, Baird DT (1981) Persistence of symptoms of premenstrual tension in hysterectomized women. Br J Obstet Gynaec 88:530-536
6. Bäckström T, Sanders D, Leask RM, Davidson D, Warner P, Bancroft J (1983) Mood, sexuality, hormones and the menstrual cycle. II. Hormone levels and their relationship to premenstrual syndrome. Psychosom Med 45:503-7
7. Bäckström T, Hansson-Malmström Y, Lindhe BA, Cavalli-Björkman B, Nordenström S (1992) Contraception 46:253-268
8. Bäckström T, Haage D, Löfgren M, Johansson IM, Strömberg J, Nyberg S, Andréen L, Ossewaarde L, Wingen GA, Turkmen S, Bengtsson SK (2011) Paradoxical effects of GABA-A modulators may explain sex steroid induced negative mood symptoms in some persons. Neuroscience 191:46-54
9. Baker LJ, O'Brien PMS (2012) Potential strategies to avoid progestogen-induced premenstrual disorders. Menopause Int 18:73-76
10. Björn I, Sundstrom-Poromaa I, Bixo M, Nyberg S, Backstrom G, Backstrom T (2003) Increase of estrogen dose deteriorates mood during progestin phase in sequential hormonal therapy. J Clin Endocrinol Metab 88:2026-30
11. Borenstein JE, Dean BB, Yonkers KA, Endicott J (2007) Using the daily record of severity of problems as a screening instrument for premenstrual syndrome. Obstet Gynecol 109:1068-75
12. Brown CS, Ling FW, Andersen RN, Farmer RG, Arheart KL (1994) Efficacy of depot leuprolide in premenstrual syndrome: effect of symptom severity and type in a controlled trial. Obstet Gynecol 84:779-86
13. Brown J, O'Brien PMS, Marjoribanks J, Wyatt K (2009) Selective serotonin reuptake inhibitors for premenstrual syndrome. Cochrane Database Syst Rev 2, CD001396
14. Busse JW, Montori VM, Krasnik C, Patelis-Siotis I, Guyatt GH (2009) Psychological intervention for premenstrual syndrome: a meta-analysis of randomized controlled trials. Psychother Psychosom 78:6-15
15. Casper RF, Hearn MT (1990) The effect of hysterectomy and bilateral oophorectomy on women with severe premenstrual syndrome. Am J Obstet Gynecol 162:105-9
16. Casson P, Hahn PM, Van Vugt DA, Reid RL (1990) Lasting response to ovariectomy in severe intractable premenstrual syndrome. Am J Obstet Gynecol 162:99-105
17. Chan AF, Mortola JF, Wood SH, Yen SS (1994) Persistence of premenstrual syndrome during low-dose administration of the progesterone antagonist RU 486. Obstet Gynecol 84:1001-1005
18. Cohen LS, Soares CN, Otto MW, Sweeney BH, Liberman RF, Harlow BL (2002a) Prevalence and predictors of premenstrual dysphoric disorder (PMDD) in older premenopausal women. The Harvard Study of Moods and Cycles. J Affect Disord 70:125-32
19. Cohen LS, Miner C, Brown EW, Freeman E, Halbreich U, Sundell K, McCray S (2002b) Premenstrual daily fluoxetine for premenstrual dysphoric disorder: a placebo-controlled, clinical trial using computerized diaries. Obstet Gynecol 100:435-444
20. Cronje WH, Vashisht A, Studd JW (2004) Hyseterctomy and bilateral oophorectomy for severe premenstrual syndrome. Hum Reprod 19:2152-5
21. Daley A (2009) Exercise and premenstrual symptomatology: a comprehensive review. J Women Health (Larchmt) 18:895-9
22. Dante G, Facchinetti F (2011) Herbal treatments for alleviating premenstrual symptoms: a systematic review. J Psychosom Obstet Gynaecol 32:42-51
23. Deeny M, Hawthorn R, McKay HD (1991) Low dose danazol in the treatment of the premenstrual syndrome. Postgrad Med J 67:450-454
24. Dennerstein L, Lehert P, Keung LS, Pal S, Choi D (2010a) Asian study of effects of premenstrual symptoms on activities of daily life. Menopause Int 16:146-151
25. Dennerstein L, Lehert P, Bäckström TC, Heinemann K (2010b) The effect of premenstrual symptoms on activities of daily life. Fertil Steril 94:1059-64
26. Dennerstein L, Lehert P, Heinemann K (2011) Global study of women's experiences of premenstrual symptoms and their effects on daily life. Menopause Int 17:88-95
27. Deuster P, Adera T, South-Paul J (1999) Biological, social, and behavioral factors associated with premenstrual syndrome. Arch Fam Med 8:122-28
28. Dimmock PW, Wyatt KM, Jones PW, O'Brien PM (2000) Efficacy of selective serotonin-reuptake inhibitors in premenstrual syndrome; a systematic review. Lancet 356:1131-6
29. Elovainio M, Teperi J, Aalto AM (2007) Depressive symptoms as predictors of discontinuation of Levonorgestrel releasing intrauterine system. Int J Behav Med 14:70-5
30. Endicott J, Nee J, Harrison W (2006) Daily record of severity of problems (DRSP): reliability and validity. Arch Womens Ment Health 9:41-9
31. Epperson CN, Haga K, Mason GF, Sellers E, Gueorguieva R, Zhang W, Weiss E, Rothman DL, Krystal JH (2002) Cortical gamma-aminobutyric acid levels across the menstrual cycle in healthy women and those with premenstrual dysphoric disorder: a proton magnetic resonance spectroscopy study. Arch Gen Psych 59:851-8
32. Epperson CN, Steiner M, Hartlage SA, Eriksoon E, Schmidt P, Jones I, Yonkers KA (2012) Premenstrual dysphoric disorder: evidence for a new category for DSM-5. Am J Psych 169:465-75
33. Eriksson E, Hedberg MA, Andersch B, Sundblad C (1995) The serotonin reuptake inhibitor paroxetin is superior to the noradrenaline reuptake inhibitor maprotiline in the treatment of premenstrual syndrome. Neuropsychopharmacology 12:167-76
34. Eriksson E, Ekman A, Sinclair S, Sörvik K, Ysander C, Mattson UB, Nissbrandt H (2008) Escitalopram administered in the luteal phase exerts a marked and dose-dependent effect in premenstrual dysphoric disorder. J Clin Psychopharmacol 28:195-202
35. Freeman EW, Sondheimer SJ, Rickels K (1997) Gonadotropin-releasing hormone agonist in the treatment of premenstrual symptoms with and without ongoing dysphoria: a controlled study. Psychopharmacol Bull 33:303-9
36. Freeman EW, Rickels K, Sondheimer SJ, Polansky M (1999) Differential response to antidepressants in women with premenstrual syndrome/premenstrual dysphoric disorder: a randomized controlled trial. Arch Gen Psychiatry 56:932-9
37. Freeman EW, Kroll R, Rapkin A, Pearlstein T, Brown C, Parsey K, Zhang P, Patel H, Foegh M (2001) Evaluation of a unique oral contraceptive in the treatment of premenstrual dysphoric disorder. J Womens Health Gend Based Med 10:561-9
38. Freeman EW, Stout AL, Endicott J, Spiers P (2002) Treatment of premenstrual syndrome with a carbohydrate-rich beverage. Int J Gynaecol Obstet 77:253-54
39. Freeman EW, Sammel MD, Lin H, Rickels K, Sondheimer J (2011) Clinical subtypes of premenstrual syndrome and responses to sertraline treatment. Obstet Gynecol 118:1293-1300
40. Freeman EW, Halbreich U, Grubb GS, Rapkin AJ, Skouby SO, Smith L, Mirkin S, Constantine GD (2012) An overview of four studies of a continuous oral contraceptive (levonorgestrel 90 mcg/ethinyl estradiol 20 mcg) on premenstrual dysphoric disorder and premenstrual syndrome. Contraception 85:437-45
41. Graham CA, Sherwin BB (1992) A prospective treatment study of premenstrual symptoms using a triphasic oral contraceptive. J Psychosom Res 36:257-66
42. Hahn PM, Van Vugt DA, Reid RL (1995) A randomized, placebo-controlled crossover trial of danazol for the treatment of premenstrual syndrome. Psychoneuroendocrinology 20:193-209
43. Halbreich U, Bergeron R, Yonkers KA, Freeman E, Stout AL, Cohen L (2002) Efficacy of intermittent, luteal phase sertraline treatment of premenstrual dysphoric disorder. Obstet Gynecol 100:1219-1229
44. Halbreich U, Borenstein J, Pearlstein T, Kahn LS (2003) The prevalence, impairment, impact, and burden of premenstrual dysphoric disorder (PMS/PMDD). Psychoneuroendocrinology 28(suppl 3):1-23
45. Halbreich U, Freeman EW, Rapkin AJ, Cohen LS, Grubb GS, Bergeron R, Smith L, Mirkin S, Constantine GD (2012) Continuous oral levonorgestrel/ethinyl estradiol for treating premenstrual dysphoric disorder. Contraception 85:19-27
46. Hammarbäck S, Bäckström T (1988) Induced anovulation as treatment of premenstrual tension syndrome. A double-blind cross-over study with GnRH-agonist versus placebo. Acta Obstet Gynecol Scand 67:159-66
47. Hammarbäck S, Bäckström T (1989) A demographic study in subgroups of women seeking help for premenstrual syndrome. Acta Obstet Gynecol Scand 68:247-53
48. Hartlage SA, Freels A, Gotman N, Yonkers KA (2012) Criteria for premenstrual dysphoric disorder (PMDD): secondary analyses of relevant data sets. Arch Gen Psychiatry 69(3):300-5
49. Howland RH (2007) Managing common side effects of SSRIs. Psychopharm 45:15-18
50. Hunter MS, Ussher JM, Cariss M, Browne S, Jelley R, Katz M (2002) Medical (fluoxetine) and psychological (cognitive-behavioural therapy) treatment for premenstrual dysphoric disorder: a study of treatment processes. J Psychosom Res 53:811-7
51. Hussain SY, Massil JH, Matta WH, Shaw RW, O'Brien PM (1992) Buserelin in premenstrual syndrome. Gynecol Endocrinol 6:57-64
52. Johnson SR, McChesney C, Bean JA (1988) Epidemiology of premenstrual symptoms in a nonclinical sample - I: prevalence, natural history and help-seeking behavior. J Repro Med 33:340-46
53. Khajehei M, Abdali K, Parsanezhad ME, Tabatabaee HR (2009) Effect of treatment with dydrogesterone or calcium plus vitamin D on the severity of premenstrual syndrome. Int J Gynaecol Obstet 105:158-61
54. Kurshan N, Epperson CN (2006) Oral contraceptives and mood in women with and without premenstrual dysphoria: a theoretical model. Arch Women Ment Health 9:1-14
55. Länden M, Nissbrandt H, Allgulander C, Sorvik K, Ysander C, Eriksson E (2007) Placebo controlled trial comparing intermittent and continuous paroxetine in premenstrual dysphoric disorder. Neuropsychopharmacology 32:153-61
56. Leather AT, Studd JWW, Watson NR, Holland EFN (1999) The treatment of severe premenstrual syndrome with goserelin with and without 'add-back' estrogen therapy: a placebo controlled study. Gynecol Endocrinol 13:48-55
57. Lopez LM, Kaptein AA, Helmerhorst FM (2009) Oral contraceptives containing drospirenone for premenstrual syndrome. Cochrane Database Syst Rev. (2):CD006586
58. Lustyk MK, Gerrish WG, Shaver S, Keys SL (2009) Cognitive-behavioral therapy for premenstrual syndrome and premenstrual dysphoric disorder: a systematic review. Arch Women Ment Health 12:85-96
59. Magos AL, Brincat M, Studd JWW (1986) Treatment of the premenstrual syndrome by subcutaneous estradiol implants and cyclical oral noresthisterone: placebo controlled study. BMJ 292:1629-33
60. Majewska MD, Harrison NL, Schwartz RD, Barker JL, Paul SM (1986) Steroid hormone metabolites are barbiturate-like modulators of the GABA receptor. Science 232:1004-1007
61. Mellon SH (1994) Neurosteroids: biochemistry, modes of action, and clinical relevance. J Clin Endocrinol Metab 78:1003-8
62. Mezrow G, Shoupe D, Spicer D, Lobo R, Leung B, Pike M (1994) Depot leuprolide acetate with estrogen and progestin add-back for long-term treatment of premenstrual syndrome. Fertil Steril 62:932-7
63. Miner C, Brown E, McCray S, Gonzales J, Wohlreich M (2002) Weekly luteal-phase dosing with enteric-coated fluoxetine 90 mg in premenstrual dysphoric disorder: a randomized, double-blind, placebo-controlled clinical trial. Clin Ther 24:417-433
64. Mitwally MF, Gotlieb L, Casper RF (2002) Prevention of bone loss and hypestrogenic symptoms by estrogen and interrupted progestogen add-back in long-term GnRH-agonist down-regulated patients with endometriosis and premenstrual syndrome. Menopause 9:236-41
65. Moret C, Isaac M, Briley M (2009) Problems associated with long-term treatment with selective serotonin reuptake inhibitors. J Psychopharm 23:967-974
66. Muse KN, Cetel NS, Futterman LA, Yen SC (1984) The premenstrual syndrome. Effects of "medical ovariectomy". N Engl J Med 311:1345-9
67. Nurnberg HG (2008) An evidence-based review updating the various treatment and management approaches to serotonin reuptake inhibitor-associated sexual dysfunction. Drugs Today 44:147-68
68. O'Brien PMS, Abukhalil IEH (1999) Randomised controlled trial of the management of premenstrual syndrome and premenstrual mastalgia using luteal phase only danazol. Am J Obstet Gynecol 180:18-23
69. O'Brien PMS, Bäckström T, Brown C, Dennerstein L, Endicott J, Neill et al (2011) Towards a consensus on diagnostic criteria, measurement and trial design of the premenstrual disorders: the ISPMD consensus. Arch Women Ment Health 14:13-21
70. Oinonen KA, Mazmanian D (2002) To what extent do oral contraceptives influence mood and affect? J Affect Disord 70:229-40
71. Olsen RW, Sieghart W (2009) GABA A receptors: subtypes provide diversity of function and pharmacology. Neuropharmacology 56:141-8
72. Parry BL, Meliska CJ, Martínez LF, López AM, Sorenson DL, Hauger RL, Elliott JA (2008) Later, but not early, wake therapy reduces morning plasma melatonin: relationship to mood in premenstrual dysphoric disorder. Psychiatry Res 30:76-86
73. Pearlstein TB, Stone AB, Lund SA, Scheft H, Zlotnick C, Brown WA (1997) Comparison of fluoxetine, bupropion, and placebo in the treatment of premenstrual dysphoric disorder. J Clin Psychopharmacol 17:261-6
74. Pearlstein TB, Bachmann GA, Zacur HA, Yonkers KA (2005) Treatment of premenstrual dysphoric disorder with a new drospirenone-containing oral contraceptive formulation. Contraception 72:414-21
75. Pincus SM, Alam S, Rubinow DR, Bhuvaneswar CG, Schmidt PJ (2011) Predicting response to leuprolide of women with premenstrual dysphoric disorder by daily mood rating dynamics. J Psychiatr Res 45:386-94
76. Ramacharan S, Love EJ, Fick GH, Goldfien A (1992) The epidemiology of premenstrual symptoms in a population based sample of 2650 urban women. J Clin Epidemiol 45:377-81
77. Rivera-Tovar AD, Frank E (1990) Late luteal phase dysphoric disorder in young women. Am J Psychiatry 147:1634-36
78. Rocha Filho EA, Lima JC, Pinho Neto JS, Montarroyos U (2011) Essential fatty acids for premenstrual syndrome and their effect on prolactin and total cholesterol levels: a randomized, double blind, placebo-controlled study. Reprod Health 8:2
79. Royal College of Obstetricians and Gynaecologists (RCOG) (2007) Management of Premenstrual Syndrome (Green-top Guideline No. 48). http://www.rcog.org.uk/files/rcog-corp/uploaded-files/ GT48ManagementPremensturalSyndrome.pdf. Accessed 10 May 2009
80. Sanders SA, Graham CA, Bass JL, Bancroft J (2001) A prospective study of the effects of oral contraceptives on sexuality and well-being and their relationship to discontinuation. Contraception 64:51-8
81. Sayegh R, Schiff I, Wurtman J, Spiers P, McDermott J, Wurtman R (1995) The effect of a carbohydrate-rich beverage on mood, appetite, and cognitive function in women with premenstrual syndrome. Obstet Gynecol 86:520-8
82. Schmidt PJ, Nieman LK, Grover GN, Muller KL, Merriam GR, Rubinow DR (1991) Lack on effect of induced menses of symptoms on women with premenstrual syndrome. N Engl J Med 324:1174-1179
83. Schmidt PJ, Grover GN, Rubinow DR (1993) Alprazolam in the treatment of premenstrual syndrome. A double-blind, placebo-controlled trial. Arch Gen Psychiatry 50:467-73
84. Schmidt PJ, Nieman LK, Danaceau MA, Adams LF, Rubinow DR (1998) Differential behavioral effects of gonadal steroids in women with and in those without premenstrual syndrome. N Engl J Med 338:209-16
85. Segebladh B, Borgström A, Nyberg S, Bixo M, Sundström-Poromaa I (2009) Evaluation of different add-back estradiol and progesterone treatments to gonadotropin-releasing hormone agonist treatment in patients with premenstrual dysphoric disorder. Am J Obstet Gynecol 201:139, e1-8
86. Shah NR, Jones JB, Aperi J, Shemtov R, Karne A, Borensstein J (2008) Selective serotonin reuptake inhibitors for premenstrual syndrome and premenstrual dysphoric disorder: a meta-analysis. Obstet Gynecol 111:1175-1182
87. Shechter A, Boivin DB (2010) Sleep, hormones, and circadian rhythms throughout the menstrual cycle in healthy women and women with premenstrual dysphoric disorder. Int J Endocrinol 2010:259345
88. Smith RNH, Studd JWW, Zamblera D, Holland EFN (1995) A randomised comparison over 8 months of 100 mcgs and 200 mcg twice weekly doses in the treatment of severe premenstrual syndrome. Br J Obstet Gynaecol 102:6475-84
89. Soares C, Cohen L, Otto M, Harlow B (2001) Characteristics of women with premenstrual dysphoric disorder (PMDD) who did or did not report history of depression: a preliminary report from the Harvard study of moods and cycles. J Women's Health Gend Based Med 10:873-78
90. Steiner M, Pearlstein T (2000) Premenstrual dysphoria and the serotonin system: pathophysiology and treatment. J Clin Psychiatry 61(Suppl 12):17-21
91. Steiner M, Macdougall M, Brown E (2003) The premenstrual symptoms screening tool (PSST) for clinicians. Arch Women Ment Health 6:203-209
92. Steiner M, Peer M, Palova E, Freeman EW, Macdougall M, Soares CN (2011) The premenstrual symptoms screening tool revised for adolescents (PSST-A): prevalence of severe PMS and premenstrual dysphoric disorder in adolescents. Arch Women Ment Health 14:77-81
93. Studd J (2011) A guide to the treatment of depression women by hormones. Climacteric 14:637-42
94. Sundblad C, Hedberg MA, Eriksson E (1993) Clomipramine administered during the luteal phase reduces the symptoms of premenstrual syndrome: a placebo-controlled trial. Neuropsychopharmacology 9:133-145
95. Sundstrom I, Nyberg S, Bixo M, Hammarbäck S, Bäckström T (1999) Treatment of premenstrual syndrome with gonadotropin-releasing hormone agonist in a low dose regimen. Acta Obstet Gynecol Scand 78:891-9
96. Sveindóttir H, Bäckström T (2000) Prevalence of menstrual cycle symptom cyclicity and premenstrual dysphoric disorder in a random sample of women using and not using oral contraceptives. Acta Obstet Gynecol Scand 79:405-13
97. Thys-Jacobs S, Starkey P, Bernstein D, Tian J (1998) Calcium carbonate and the premenstrual syndrome: effects of premenstrual and menstrual symptoms. Premenstrual Syndrome Study Group Am J Obstet Gynecol 179:444-52
98. Watson NR, Studd JWW, Savvas M, Garnett T, Baber RJ (1989) Treatment of severe pre-menstrual syndrome with estradiol patched and cyclical oral noresthisterone. Lancet ii:730-734
99. West CP, Hillier H (1994) Ovarian suppression with the gonadotrophin-releasing hormone agonist goserelin (Zoladex) in management of the premenstrual tension syndrome. Hum Reprod 9:1058-63
100. Whelan AM, Jurgens TM, Naylor H (2009) Herbs, vitamins and minerals in the treatment of premenstrual syndrome: a systematic review. Can J Clin Pharmacol 16:407-29
101. Wittchen HU, Becker E, Lieb R, Krause P (2002) Prevalence, incidence and stability of premenstrual dysphoric disorder in the community. Psychol Med 32:119-132
102. Woods NF, Most A, Dery GK (1982) Prevalence of perimenstrual symptoms. Am J Public Health 72:1257-64
103. Wyatt KM, Dimmock PW, Jones PW, O'Brien PMS (1999) Efficacy of vitamin B-6 in the treatment of premenstrual syndrome: systematic review. BMJ 318:1375-81
104. Wyatt KM, Dimmock PW, Ismail KM, Jones PW, O'Brien PM (2004) The effectiveness of GnRHa with and without 'add-back' therapy in treating premenstrual syndrome: a meta-analysis. BJOG 111:585-93
105. Yonkers KA, Brown C, Pearlstein TB, Foegh M, Sampson-Landers C, Rapkin A (2005) Efficacy of a new low-dose oral contraceptive with drospirenone in premenstrual dysphoric disorder. Obstet Gynecol 106:492-501
106. Yonkers KA, O'Brien PMS, Eriksson E (2008) Premenstrual syndrome. Lancet 371:1200-10